<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04088474</url>
  </required_header>
  <id_info>
    <org_study_id>Sunway002</org_study_id>
    <nct_id>NCT04088474</nct_id>
  </id_info>
  <brief_title>Effects of Vigiis 101-LAB on a Healthy Populations' Gut Microflora</brief_title>
  <official_title>Functional Assessment in The Intestinal Flora Improvement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SunWay Biotech Co., LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SunWay Biotech Co., LTD.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial was conducted as part of the &quot;Methods for Evaluating the Improvement of
      Gastrointestinal Function in Health Food&quot; announced by the Department of Health, DOH
      (currently known as Ministry of Health and Welfare, MOHW) on the test article, &quot;Vigiis
      101-LAB powder (Capsules)&quot;, manufactured by SunWay Biotech Co., Ltd.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1.1 Introduction The human microbiome comprises diverse microbiologic ecosystems and is
      composed of a variety of bacteria, archaea, microeukaryotes, and viruses. Although
      investigators have appreciated the diversity of our microbial world for decades, scientists
      were constrained by the inability to culture many bacteria in the laboratory. Paradigms in
      biomedical science and medicine are changing in a fundamental way as investigators explore
      potential contributions of human-associated microbes to health and expand our understanding
      of disease susceptibility and pathogenesis. In the 21st century, investigators are attempting
      to develop a more balanced mindset as investigators seek to understand the role of the human
      microbiome in physiology and manipulate it to optimize health and prevent or treat disease.
      In recent years, investigators have increased our understanding of microbial communities and
      their corresponding metagenomes at different human body sites greatly. Healthy
      gastrointestinal (GI) microbiome should include age, sex, race/ethnicity, and diet. The Human
      Microbiome Project documented the importance of considering sex and race/ethnicity in
      evaluating differences between microbiomes of individuals. The human GI microbiome comprises
      diverse microbial communities that differ based on their location along the length of the GI
      tract (esophagus, stomach, small intestine, and large intestine or colon). Most human
      intestinal microbiome studies have relied on stool specimens. Probiotics have showed to
      possess anti mutagenic, anti carcinogenic and hypocholesterolemic properties. It is
      well-known that probiotics have a number of beneficial health effects in humans and animals,
      including the reduction of symptoms in lactose intolerance and enhancement of the bio
      availability of nutrients. Further, they were also observed to have antagonistic actions
      against intestinal and food-borne pathogens, to decrease the prevalence of allergies in
      susceptible individuals and to have immunomodulatory effects. Typically, the bacteria
      colonise the intestinal tract first and then reinforce the host defence systems by inducing a
      generalised mucosal immune response, balanced T-helper cell response, self-limited
      inflammatory response and secretion of polymeric IgA. Scientific reports showed that the
      Taiwan native lactic acid bacterium from newborn infant faeces identified as Lactobacillus
      paracasei subsp. paracasei NTU 101 and its fermented products proved to be effective for the
      management of blood cholesterol and pressure, prevention of gastric mucosal lesion
      development, immunomodulation and alleviation of allergies, anti-osteoporosis and inhibition
      the fat tissue accumulation.

      1.2 Materials The strain used in the current study was L. paracasei subsp. paracasei NTU 101
      (lyophilized powdered, Vigiis 101-LAB; probiotic powder from SunWay Biotech Co., Ltd.,
      Taipei, Taiwan). The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were
      made into capsules (Vigiis 101-LAB capsule) containing 5 billion bacteria per capsule for the
      gut flora clinical trial. Maltodextrin was used as a placebo.

      1.3 Randomized, double-blind clinical criteria of effects of Vigiis 101-LAB capsule I on gut
      flora (clinical trial) Vigiis 101-LAB capsule was administered orally once per day, one
      capsule each time. The entire study took 4 weeks, and subjects were prohibited from eating
      fermented food products, such as miso, kimchi, fermented dairy products,
      oligosaccharide-containing foods, and lactic acid bacteria-containing products. Subjects also
      avoided consuming excessive gas-producing foods (such as soybeans and sweet potatoes) during
      their daily meals and avoided foods that can cause abdominal distension or promote
      peristalsis (such as lactic acid beverages and oligosaccharide-containing beverages). After
      the trial started, subjects recorded their daily number of bowel movements and completed
      relevant questionnaires at weeks 0, 2, and 4. The subjects visited the doctor once every 2
      weeks for monitoring gastrointestinal function and physiological characteristics. At weeks 0,
      1, 2, 3, and 4, fecal samples from the subjects were collected and put into bottles
      containing an anaerobic diluent and shaken to uniformly mix the feces and diluent.

      1.4 Outcome measurements Fecal moisture content and pH value testing. Blood biochemical tests
      were carried out in the laboratory.

      1.5. Statistical analysis Data are expressed as the mean ± standard deviation (SD). The
      statistical significance of the biochemical analyses was determined by one-way analysis of
      variance (ANOVA) using the general linear model procedure of the statistical product and
      service solutions software (SPSS Institute, Inc., Chicago, IL, USA). This was followed by
      ANOVA with a paired t-test to evaluate the difference before and after sample and placebo
      administration, while the Student t-test was used to compare the difference between test and
      placebo groups (P ≤ 0.05).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 5, 2016</start_date>
  <completion_date type="Actual">December 18, 2016</completion_date>
  <primary_completion_date type="Actual">July 6, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>a randomized, double-blind, placebo-controlled clinical study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>a randomized, double-blind, placebo-controlled clinical study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Microflora analysis of fecal contents</measure>
    <time_frame>4 week</time_frame>
    <description>culture for intestinal defecation Bifidobacterium spp. Clostridium perfringens. Lactobacillus spp. and Escherichia coli</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Gastrointestinal Microbiome</condition>
  <arm_group>
    <arm_group_label>Vigiis 101-LAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were made into capsules (Vigiis 101-LAB capsule I) containing 5 billion bacteria per capsule for the gut flora clinical trial. The Vigiis 101-LAB mixed lactose, crystalline cellulose, and excipient were also mixed into capsules (Vigiis 101- LAB capsule II) containing 5 billion bacteria per capsule for clinical trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin was used as a placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vigiis 101-LAB</intervention_name>
    <description>examined the effects of the Vigiis 101-LAB capsules (5 billion CFU/day)</description>
    <arm_group_label>Vigiis 101-LAB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Maltodextrin was used as a placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adults aged ≧ 20 years and ≦ 65 years.

          2. Subjects with normal weight (body mass index: 18.5-24).

          3. Subjects with no gastrointestinal diseases or on medication.

        Exclusion Criteria:

          1. Pregnant or lactating women.

          2. Subjects who are allergic to Lactobacillus.

          3. Subjects with chronic gastrointestinal diseases.

          4. Subjects who previously underwent gastrectomy or gastric bypass.

          5. Subjects with liver, kidney, or heart disease, alcoholism, or uncontrolled diabetes.

          6. Subjects who developed stroke, psychiatric diseases, or depression within the last 1
             year.

          7. Subjects being administered drugs that can regulate gastrointestinal function,
             functional foods, bacteriostatic drugs or supplements, antibiotics, antioxidants, or
             other unknown drugs within the last 2 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jyh Ming Liou, MD,PHD</last_name>
    <role>Study Director</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tsong Ming Lu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cheng Hsin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine</name>
      <address>
        <city>Taipei</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Agace WW, McCoy KD. Regionalized Development and Maintenance of the Intestinal Adaptive Immune Landscape. Immunity. 2017 Apr 18;46(4):532-548. doi: 10.1016/j.immuni.2017.04.004. Review.</citation>
    <PMID>28423335</PMID>
  </results_reference>
  <results_reference>
    <citation>Arnao MB, Cano A, Hernández-Ruiz J, García-Cánovas F, Acosta M. Inhibition by L-ascorbic acid and other antioxidants of the 2.2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) oxidation catalyzed by peroxidase: a new approach for determining total antioxidant status of foods. Anal Biochem. 1996 May 1;236(2):255-61.</citation>
    <PMID>8660502</PMID>
  </results_reference>
  <results_reference>
    <citation>Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, Cheng G, Yamasaki S, Saito T, Ohba Y, Taniguchi T, Takeda K, Hori S, Ivanov II, Umesaki Y, Itoh K, Honda K. Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 2011 Jan 21;331(6015):337-41. doi: 10.1126/science.1198469. Epub 2010 Dec 23.</citation>
    <PMID>21205640</PMID>
  </results_reference>
  <results_reference>
    <citation>Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014 Mar 27;157(1):121-41. doi: 10.1016/j.cell.2014.03.011. Review.</citation>
    <PMID>24679531</PMID>
  </results_reference>
  <results_reference>
    <citation>Belkaid Y, Harrison OJ. Homeostatic Immunity and the Microbiota. Immunity. 2017 Apr 18;46(4):562-576. doi: 10.1016/j.immuni.2017.04.008. Review.</citation>
    <PMID>28423337</PMID>
  </results_reference>
  <results_reference>
    <citation>Bengmark S. Gut microbiota, immune development and function. Pharmacol Res. 2013 Mar;69(1):87-113. doi: 10.1016/j.phrs.2012.09.002. Epub 2012 Sep 16. Review.</citation>
    <PMID>22989504</PMID>
  </results_reference>
  <results_reference>
    <citation>Bridgman SL, Azad MB, Field CJ, Haqq AM, Becker AB, Mandhane PJ, Subbarao P, Turvey SE, Sears MR, Scott JA, Wishart DS, Kozyrskyj AL; CHILD Study Investigators. Fecal Short-Chain Fatty Acid Variations by Breastfeeding Status in Infants at 4 Months: Differences in Relative versus Absolute Concentrations. Front Nutr. 2017 Apr 10;4:11. doi: 10.3389/fnut.2017.00011. eCollection 2017.</citation>
    <PMID>28443284</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen T, Isomäki P, Rimpiläinen M, Toivanen P. Human cytokine responses induced by gram-positive cell walls of normal intestinal microbiota. Clin Exp Immunol. 1999 Nov;118(2):261-7.</citation>
    <PMID>10540188</PMID>
  </results_reference>
  <results_reference>
    <citation>Kopp-Hoolihan L. Prophylactic and therapeutic uses of probiotics: a review. J Am Diet Assoc. 2001 Feb;101(2):229-38; quiz 239-41. Review.</citation>
    <PMID>11271697</PMID>
  </results_reference>
  <results_reference>
    <citation>Krasowska A, Sigler K. How microorganisms use hydrophobicity and what does this mean for human needs? Front Cell Infect Microbiol. 2014 Aug 19;4:112. doi: 10.3389/fcimb.2014.00112. eCollection 2014. Review.</citation>
    <PMID>25191645</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee N, Kim WU. Microbiota in T-cell homeostasis and inflammatory diseases. Exp Mol Med. 2017 May 26;49(5):e340. doi: 10.1038/emm.2017.36. Review.</citation>
    <PMID>28546563</PMID>
  </results_reference>
  <results_reference>
    <citation>Dement JM, Epling C, Joyner J, Cavanaugh K. Impacts of Workplace Health Promotion and Wellness Programs on Health Care Utilization and Costs: Results From an Academic Workplace. J Occup Environ Med. 2015 Nov;57(11):1159-69. doi: 10.1097/JOM.0000000000000555.</citation>
    <PMID>26539763</PMID>
  </results_reference>
  <results_reference>
    <citation>Lin FM, Chiu CH, Pan TM. Fermentation of a milk-soymilk and Lycium chinense Miller mixture using a new isolate of Lactobacillus paracasei subsp. paracasei NTU101 and Bifidobacterium longum. J Ind Microbiol Biotechnol. 2004 Dec;31(12):559-64. Epub 2004 Nov 18.</citation>
    <PMID>15662546</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu CF, Tung YT, Wu CL, Lee BH, Hsu WH, Pan TM. Antihypertensive effects of Lactobacillus-fermented milk orally administered to spontaneously hypertensive rats. J Agric Food Chem. 2011 May 11;59(9):4537-43. doi: 10.1021/jf104985v. Epub 2011 Apr 4.</citation>
    <PMID>21446645</PMID>
  </results_reference>
  <results_reference>
    <citation>Lobo V, Patil A, Phatak A, Chandra N. Free radicals, antioxidants and functional foods: Impact on human health. Pharmacogn Rev. 2010 Jul;4(8):118-26. doi: 10.4103/0973-7847.70902.</citation>
    <PMID>22228951</PMID>
  </results_reference>
  <results_reference>
    <citation>Miller NJ, Sampson J, Candeias LP, Bramley PM, Rice-Evans CA. Antioxidant activities of carotenes and xanthophylls. FEBS Lett. 1996 Apr 22;384(3):240-2.</citation>
    <PMID>8617362</PMID>
  </results_reference>
  <results_reference>
    <citation>Naidu AS, Bidlack WR, Clemens RA. Probiotic spectra of lactic acid bacteria (LAB). Crit Rev Food Sci Nutr. 1999 Jan;39(1):13-126. Review.</citation>
    <PMID>10028126</PMID>
  </results_reference>
  <results_reference>
    <citation>Orrhage K, Sillerström E, Gustafsson JA, Nord CE, Rafter J. Binding of mutagenic heterocyclic amines by intestinal and lactic acid bacteria. Mutat Res. 1994 Dec 1;311(2):239-48.</citation>
    <PMID>7526189</PMID>
  </results_reference>
  <results_reference>
    <citation>Ouwehand AC, Isolauri E, Kirjavainen PV, Tölkko S, Salminen SJ. The mucus binding of Bifidobacterium lactis Bb12 is enhanced in the presence of Lactobacillus GG and Lact. delbrueckii subsp. bulgaricus. Lett Appl Microbiol. 2000 Jan;30(1):10-3.</citation>
    <PMID>10728552</PMID>
  </results_reference>
  <results_reference>
    <citation>Ouwehand AC, Salminen S, Isolauri E. Probiotics: an overview of beneficial effects. Antonie Van Leeuwenhoek. 2002 Aug;82(1-4):279-89. Review.</citation>
    <PMID>12369194</PMID>
  </results_reference>
  <results_reference>
    <citation>Pant N, Marcotte H, Brüssow H, Svensson L, Hammarström L. Effective prophylaxis against rotavirus diarrhea using a combination of Lactobacillus rhamnosus GG and antibodies. BMC Microbiol. 2007 Sep 27;7:86.</citation>
    <PMID>17900343</PMID>
  </results_reference>
  <results_reference>
    <citation>Perdigón G, Vintiñi E, Alvarez S, Medina M, Medici M. Study of the possible mechanisms involved in the mucosal immune system activation by lactic acid bacteria. J Dairy Sci. 1999 Jun;82(6):1108-14.</citation>
    <PMID>10386296</PMID>
  </results_reference>
  <results_reference>
    <citation>Pool-Zobel BL, Neudecker C, Domizlaff I, Ji S, Schillinger U, Rumney C, Moretti M, Vilarini I, Scassellati-Sforzolini R, Rowland I. Lactobacillus- and bifidobacterium-mediated antigenotoxicity in the colon of rats. Nutr Cancer. 1996;26(3):365-80.</citation>
    <PMID>8910918</PMID>
  </results_reference>
  <results_reference>
    <citation>Rafter J. The effects of probiotics on colon cancer development. Nutr Res Rev. 2004 Dec;17(2):277-84. doi: 10.1079/NRR200484.</citation>
    <PMID>19079931</PMID>
  </results_reference>
  <results_reference>
    <citation>Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet. 1994 Oct 15;344(8929):1046-9.</citation>
    <PMID>7934445</PMID>
  </results_reference>
  <results_reference>
    <citation>Sekine K, Toida T, Saito M, Kuboyama M, Kawashima T, Hashimoto Y. A new morphologically characterized cell wall preparation (whole peptidoglycan) from Bifidobacterium infantis with a higher efficacy on the regression of an established tumor in mice. Cancer Res. 1985 Mar;45(3):1300-7.</citation>
    <PMID>3971375</PMID>
  </results_reference>
  <results_reference>
    <citation>Sheng Y, Yang X, Lian Y, Zhang B, He X, Xu W, Huang K. Characterization of a cadmium resistance Lactococcus lactis subsp. lactis strain by antioxidant assays and proteome profiles methods. Environ Toxicol Pharmacol. 2016 Sep;46:286-291. doi: 10.1016/j.etap.2016.08.008. Epub 2016 Aug 6.</citation>
    <PMID>27522548</PMID>
  </results_reference>
  <results_reference>
    <citation>Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, Glickman JN, Garrett WS. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013 Aug 2;341(6145):569-73. doi: 10.1126/science.1241165. Epub 2013 Jul 4.</citation>
    <PMID>23828891</PMID>
  </results_reference>
  <results_reference>
    <citation>Stecher B. The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric Pathogen Infection. Microbiol Spectr. 2015 Jun;3(3). doi: 10.1128/microbiolspec.MBP-0008-2014.</citation>
    <PMID>26185088</PMID>
  </results_reference>
  <results_reference>
    <citation>Sun Y, O'Riordan MX. Regulation of bacterial pathogenesis by intestinal short-chain Fatty acids. Adv Appl Microbiol. 2013;85:93-118. doi: 10.1016/B978-0-12-407672-3.00003-4. Review.</citation>
    <PMID>23942149</PMID>
  </results_reference>
  <results_reference>
    <citation>Tomkovich S, Jobin C. Microbiota and host immune responses: a love-hate relationship. Immunology. 2016 Jan;147(1):1-10. doi: 10.1111/imm.12538. Epub 2015 Nov 2. Review.</citation>
    <PMID>26439191</PMID>
  </results_reference>
  <results_reference>
    <citation>Tsai TY, Chu LH, Lee CL, Pan TM. Atherosclerosis-preventing activity of lactic acid bacteria-fermented milk-soymilk supplemented with Momordica charantia. J Agric Food Chem. 2009 Mar 11;57(5):2065-71. doi: 10.1021/jf802936c.</citation>
    <PMID>19216552</PMID>
  </results_reference>
  <results_reference>
    <citation>Tsai YT, Cheng PC, Fan CK, Pan TM. Time-dependent persistence of enhanced immune response by a potential probiotic strain Lactobacillus paracasei subsp. paracasei NTU 101. Int J Food Microbiol. 2008 Dec 10;128(2):219-25. doi: 10.1016/j.ijfoodmicro.2008.08.009. Epub 2008 Aug 26.</citation>
    <PMID>18809220</PMID>
  </results_reference>
  <results_reference>
    <citation>Tuson HH, Weibel DB. Bacteria-surface interactions. Soft Matter. 2013 May 14;9(18):4368-4380.</citation>
    <PMID>23930134</PMID>
  </results_reference>
  <results_reference>
    <citation>Van de Water J, Keen CL, Gershwin ME. The influence of chronic yogurt consumption on immunity. J Nutr. 1999 Jul;129(7 Suppl):1492S-5S. doi: 10.1093/jn/129.7.1492S. Erratum in: J Nutr 1999 Oct;129(10):1932.</citation>
    <PMID>10395628</PMID>
  </results_reference>
  <results_reference>
    <citation>Yu X, Li S, Yang D, Qiu L, Wu Y, Wang D, Shah NP, Xu F, Wei H. A novel strain of Lactobacillus mucosae isolated from a Gaotian villager improves in vitro and in vivo antioxidant as well as biological properties in D-galactose-induced aging mice. J Dairy Sci. 2016 Feb;99(2):903-914. doi: 10.3168/jds.2015-10265. Epub 2015 Dec 17.</citation>
    <PMID>26709186</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 5, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gut microflora</keyword>
  <keyword>Lactobacillus paracasei subsp. paracasei NTU 101</keyword>
  <keyword>probiotics</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Effects of Vigiis 101-LAB capsule on improving gut microflora was examined</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>starting 6 months after publication</ipd_time_frame>
    <ipd_access_criteria>Medicine / Nursing Medical Doctor Healthcare / Medical Management Medical Technician Pharmacist Nurse / Nursing Personnel Clinical Coodinator Clinical Researcher</ipd_access_criteria>
  </patient_data>
  <pending_results>
    <submitted>September 24, 2019</submitted>
    <returned>October 18, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

